Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triapine and Fludarabine in Aggressive Myeloproliferative Disorders
NCT00381550Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2006
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of triapine in myeloproliferative disorder (MPD), chronic myelomonocytic leukemia (CMML) and chronic myelogenous leukemia (CML), sponsored by National Cancer Institute. Primary endpoint: Response Rate at 4 years. Started Aug 2006; status: completed.
02
Drugs
triapine
03
Conditions
myeloproliferative disorder (MPD)chronic myelomonocytic leukemia (CMML)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00381550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00381550.